Ignite Creation Date:
2024-05-06 @ 8:17 PM
Last Modification Date:
2024-10-26 @ 3:24 PM
Study NCT ID:
NCT06328283
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-03-25
First Post:
2024-03-18
Brief Title:
The Diagnostic Efficacy of Glutamine Synthetaseand BCLAF1in Early Diagosis of Hepatocellular Carcinoma in Cirrhotic Patients
Sponsor:
Sohag University
Organization:
Sohag University
Study Overview
Official Title:
The Diagnostic Efficacy of Glutamine Synthetaseand BCLAF1in Early Diagosis of GLutamine Synthetase and BCLAF1 in Diagnosis of Hepatocellular in Cirrhotic Patients
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Hepatocellular carcinoma HCC is the most prominent kind of liver cancer accounting for 85 of primary liver malignancies It is a very aggressive tumor having a terrible prognosis and poor survival rate HCC is ranked as the sixth most common type of cancer and the third leading cause of cancer-related mortalities world wide
HCC incidences arise in complications associated with chronic liver disease like cirrhosis endemic hepatitis B virus HBVhepatitis C virus HCV infections non alcoholic fatty liver disease NAFLD and alcohol-related liver disease Torre 2015
HCC incidences arise in complications associated with chronic liver disease like cirrhosis endemic hepatitis B virus HBVhepatitis C virus HCV infections non alcoholic fatty liver disease NAFLD and alcohol-related liver disease Torre 2015
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None